AU2020253444C1 - Pyrrole compounds - Google Patents

Pyrrole compounds

Info

Publication number
AU2020253444C1
AU2020253444C1 AU2020253444A AU2020253444A AU2020253444C1 AU 2020253444 C1 AU2020253444 C1 AU 2020253444C1 AU 2020253444 A AU2020253444 A AU 2020253444A AU 2020253444 A AU2020253444 A AU 2020253444A AU 2020253444 C1 AU2020253444 C1 AU 2020253444C1
Authority
AU
Australia
Prior art keywords
unsubstituted
substituted
alkyl
compound
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020253444A
Other languages
English (en)
Other versions
AU2020253444B2 (en
AU2020253444A1 (en
Inventor
Franck Amblard
Leda BASSIT
Leonid Beigelman
Raymond F. Schinazi
Vladimir Serebryany
David Bernard Smith
Sandrine Vendeville
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emory University
Aligos Therapeutics Inc
Original Assignee
Emory University
Aligos Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emory University, Aligos Therapeutics Inc filed Critical Emory University
Publication of AU2020253444A1 publication Critical patent/AU2020253444A1/en
Publication of AU2020253444B2 publication Critical patent/AU2020253444B2/en
Priority to AU2025217289A priority Critical patent/AU2025217289A1/en
Application granted granted Critical
Publication of AU2020253444C1 publication Critical patent/AU2020253444C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/094—Esters of phosphoric acids with arylalkanols

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2020253444A 2019-04-03 2020-04-01 Pyrrole compounds Active AU2020253444C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025217289A AU2025217289A1 (en) 2019-04-03 2025-08-13 Pyrrole compounds

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962828919P 2019-04-03 2019-04-03
US62/828,919 2019-04-03
US201962932686P 2019-11-08 2019-11-08
US62/932,686 2019-11-08
PCT/US2020/026116 WO2020205934A1 (en) 2019-04-03 2020-04-01 Pyrrole compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025217289A Division AU2025217289A1 (en) 2019-04-03 2025-08-13 Pyrrole compounds

Publications (3)

Publication Number Publication Date
AU2020253444A1 AU2020253444A1 (en) 2021-10-14
AU2020253444B2 AU2020253444B2 (en) 2025-05-29
AU2020253444C1 true AU2020253444C1 (en) 2025-12-11

Family

ID=72667046

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2020253444A Active AU2020253444C1 (en) 2019-04-03 2020-04-01 Pyrrole compounds
AU2025217289A Pending AU2025217289A1 (en) 2019-04-03 2025-08-13 Pyrrole compounds

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025217289A Pending AU2025217289A1 (en) 2019-04-03 2025-08-13 Pyrrole compounds

Country Status (22)

Country Link
US (3) US11191747B2 (https=)
EP (2) EP4733305A2 (https=)
JP (3) JP7627008B2 (https=)
KR (2) KR20260036605A (https=)
CN (4) CN121108187A (https=)
AU (2) AU2020253444C1 (https=)
BR (1) BR112021019817A2 (https=)
CA (1) CA3134635A1 (https=)
CL (1) CL2021002575A1 (https=)
CO (1) CO2021014210A2 (https=)
DK (1) DK3947349T3 (https=)
FI (1) FI3947349T3 (https=)
GE (2) GEP20257772B (https=)
IL (1) IL286902B2 (https=)
MA (1) MA55564A (https=)
MX (1) MX2021012105A (https=)
PE (1) PE20220252A1 (https=)
PH (1) PH12021552513A1 (https=)
SG (1) SG11202110718PA (https=)
TW (1) TWI846853B (https=)
UA (1) UA129029C2 (https=)
WO (1) WO2020205934A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121108187A (zh) 2019-04-03 2025-12-12 阿里戈斯治疗公司 吡咯化合物
CN114685514A (zh) * 2020-12-29 2022-07-01 广东东阳光药业有限公司 新型酰胺吡咯类化合物及其在药物中的应用
WO2022156758A1 (zh) * 2021-01-22 2022-07-28 广东东阳光药业有限公司 新型酰胺吡咯类化合物及其在药物中的用途
CA3231695A1 (en) 2021-09-08 2023-03-16 Aligos Therapeutics, Inc. Modified short interfering nucleic acid (sina) molecules and uses thereof
CN118974014B (zh) * 2022-03-17 2026-01-27 成都微芯药业有限公司 吡咯酰胺类化合物及其制备方法和用途
CN116120219A (zh) * 2022-12-27 2023-05-16 吉斯凯(苏州)制药有限公司 一种多取代吡咯类化合物及其制备方法和在制备hbv衣壳蛋白抑制剂中的应用
JP2026503674A (ja) * 2023-01-26 2026-01-29 アリゴス セラピューティクス インコーポレイテッド Ｂ型肝炎併用療法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015011281A1 (en) * 2013-07-25 2015-01-29 Janssen R&D Ireland Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
WO2017156255A1 (en) * 2016-03-09 2017-09-14 Emory University Elimination of hepatitis b virus with antiviral agents
WO2018039531A1 (en) * 2016-08-26 2018-03-01 Gilead Sciences, Inc. Substituted pyrrolizine compounds and uses thereof

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4784782A (en) 1986-03-27 1988-11-15 The Lubrizol Corporation Heterocyclic compounds useful as additives for lubricant and fuel compositions
BR0112826A (pt) 2000-07-17 2003-06-24 Ranbaxy Lab Ltd Derivados da oxazolidinona como antimicrobianos
EP1389209B1 (en) 2001-04-24 2009-04-08 Purdue Research Foundation Folate mimetics and folate-receptor binding conjugates thereof
US6956040B2 (en) 2001-07-16 2005-10-18 Ranbaxy Laboratories Limited Oxazolidinone piperazinyl derivatives as potential antimicrobials
GB0119172D0 (en) 2001-08-06 2001-09-26 Melacure Therapeutics Ab Phenyl pyrrole derivatives
ZA200505523B (en) 2002-12-20 2006-09-27 Amgen Inc Asthma and allergic inflammation modulators
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
GB2398299A (en) 2003-02-13 2004-08-18 Melacure Therapeutics Ab Pharmaceutically active phenyl-pyrrole derivatives
US20070191336A1 (en) 2003-12-24 2007-08-16 Flynn Daniel L Anti-inflammatory medicaments
US7732446B1 (en) 2004-03-11 2010-06-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
AU2005221959C1 (en) 2004-03-13 2010-06-17 Kyoto University Novel indole derivative for alkylating specific base sequence of DNA and alkylating agent and drug each comprising the same
US20060102471A1 (en) 2004-11-18 2006-05-18 Karl Maurer Electrode array device having an adsorbed porous reaction layer
US20060105355A1 (en) 2004-11-18 2006-05-18 Karl Maurer Electrode array device having an adsorbed porous reaction layer having a linker moiety
US8835476B2 (en) 2005-03-04 2014-09-16 Fan Wu Synthesis of novel antimicrobials
US20100234379A1 (en) 2005-07-28 2010-09-16 Bahr Ben A Dual modulation of endocannabinoid transport and fatty-acid amide hydrolase for treatment of excitotoxicity
US20070065877A1 (en) 2005-09-19 2007-03-22 Combimatrix Corporation Microarray having a base cleavable succinate linker
KR101507375B1 (ko) 2006-09-15 2015-04-07 엑스커버리 홀딩 컴퍼니 엘엘씨 키나아제 억제제 화합물
EP2155720B1 (en) 2007-06-08 2013-07-17 Advinus Therapeutics Private Limited Pyrrole-2-carboxamide derivatives as glucokinase activators, their process and pharmaceutical application
CN101679358B (zh) 2007-06-18 2013-10-30 塞诺菲-安万特股份有限公司 作为p2y12拮抗剂的吡咯衍生物
CA2754492A1 (en) 2009-03-05 2010-09-10 Purdue Research Foundation Method for early imaging of atherosclerosis
WO2010107736A2 (en) 2009-03-20 2010-09-23 University Of Virginia Patent Foundation Broad spectrum benzothiophene-nitrothiazolide and other antimicrobials
BR112012009576A2 (pt) 2009-10-22 2019-09-24 Univ Vanderbilt potencializador alostérico de mglur4, composições, e métodos de tratamento de disfunção neurológica
BR112012028894A2 (pt) 2010-05-12 2019-09-24 Univ Vanderbilt sulfona heterocíclica como potenciadores alostéricos de mglur4, composições e métodos de tratamento de disfunção neurológica
KR20130087495A (ko) 2010-06-15 2013-08-06 바이엘 인텔렉쳐 프로퍼티 게엠베하 안트라닐산 유도체
MX2013002895A (es) 2010-09-14 2013-06-05 Inst Biochemii I Biofizyki Pan Compuestos como moduladores de una proteina cftr mutante y su uso para tratar enfermedades asociadas con las deficiencias de la proteina cftr.
WO2012047525A2 (en) 2010-09-27 2012-04-12 Endocyte, Inc. Folate conjugates for treating inflammation of the eye
WO2012078902A2 (en) 2010-12-08 2012-06-14 Proteostasis Therapeutics, Inc. Proteostasis regulators
WO2012087976A2 (en) 2010-12-21 2012-06-28 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
US20130072473A1 (en) 2011-05-09 2013-03-21 Proteostasis Therapeutics, Inc. Compounds for treating protein folding disorders
WO2012154880A1 (en) 2011-05-09 2012-11-15 Proteostasis Therapeutics, Inc. Proteostasis regulators for treating cystic fibrosis and other protein misfolding diseases
DK2707101T3 (da) 2011-05-12 2019-05-13 Proteostasis Therapeutics Inc Proteostaseregulatorer
EP3085368A1 (en) 2011-07-01 2016-10-26 Baruch S. Blumberg Institute Sulfamoylbenzamide derivatives as antiviral agents against hbv infection
US8835640B1 (en) 2011-11-16 2014-09-16 Paresh T. Gandhi Nicotine derivatives
HK1210969A1 (en) 2012-01-20 2016-05-13 奥克塞拉有限公司 Substituted heterocyclic compounds for disease treatment
EP3345597A3 (en) 2012-09-19 2018-08-22 Faller & Williams Technology, LLC Pkc delta inhibitors for use as therapeutics
TWI651300B (zh) 2013-05-17 2019-02-21 健生科學愛爾蘭無限公司 胺磺醯基吡咯醯胺衍生物及其作為用於治療ｂ型肝炎藥物的用途
KR102290189B1 (ko) 2013-10-23 2021-08-17 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 카르복스아미드 유도체 및 ｂ형 간염 치료용 의약으로서의 이의 용도
CN104672221B (zh) 2013-11-29 2018-01-23 中国科学院上海有机化学研究所 一种氟代苯并杂环‑杂芳环结构的合成方法
US10040780B2 (en) 2014-03-03 2018-08-07 The Regents Of The University Of California Mcl-1 antagonists
DE102014108210A1 (de) 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
US20160166679A1 (en) 2014-12-12 2016-06-16 Purdue Research Foundation Method of treatment using folate conjugates and tyrosine kinase inhibitors
KR101726059B1 (ko) 2015-07-28 2017-04-12 한양대학교 산학협력단 디피롤 유도체와 암모늄 염을 포함하는 브롬화수소 가스 검출용 조성물 및 이를 포함하는 브롬화수소 가스 검출용 색변환 센서
KR101726060B1 (ko) 2015-07-28 2017-04-12 한양대학교 산학협력단 디피롤 유도체와 금속 염을 포함하는 염화수소 가스 검출용 조성물 및 이를 포함하는 염화수소 가스 검출용 색변환 센서
WO2017081615A1 (en) 2015-11-09 2017-05-18 Wockhardt Limited 7-oxo -6-(sulfooxy)- 1,6-diazabicyclo [3.2.1] octane containing compounds and their use in treatment of bacterial infections
CN108250121A (zh) 2016-12-28 2018-07-06 上海长森药业有限公司 磺酰胺-芳基酰胺类化合物及其治疗乙型肝炎的药物用途
CN115974753A (zh) 2018-03-30 2023-04-18 正大天晴药业集团股份有限公司 含有n杂五元环化合物和用途
BR112021006403A2 (pt) 2018-10-05 2021-07-06 Univ Emory agentes monômeros e multiméricos anti-hbv
MX2021010145A (es) 2019-02-22 2021-09-14 Janssen Sciences Ireland Unlimited Co Derivados de amida utiles en el tratamiento de una infeccion por vhb o de enfermedades inducidas por vhb.
CN121108187A (zh) 2019-04-03 2025-12-12 阿里戈斯治疗公司 吡咯化合物
AU2020385034B2 (en) 2019-11-13 2024-11-14 Xi'an Xintong Pharmaceutical Research Co., Ltd. HBV inhibitor and use thereof
CN114685514A (zh) 2020-12-29 2022-07-01 广东东阳光药业有限公司 新型酰胺吡咯类化合物及其在药物中的应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015011281A1 (en) * 2013-07-25 2015-01-29 Janssen R&D Ireland Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
WO2017156255A1 (en) * 2016-03-09 2017-09-14 Emory University Elimination of hepatitis b virus with antiviral agents
WO2018039531A1 (en) * 2016-08-26 2018-03-01 Gilead Sciences, Inc. Substituted pyrrolizine compounds and uses thereof

Also Published As

Publication number Publication date
EP3947349A1 (en) 2022-02-09
US20230390242A1 (en) 2023-12-07
US11191747B2 (en) 2021-12-07
TW202102474A (zh) 2021-01-16
KR102933784B1 (ko) 2026-03-06
CN121108187A (zh) 2025-12-12
JP7811768B2 (ja) 2026-02-06
AU2025217289A1 (en) 2025-09-04
GEP20257772B (en) 2025-06-10
KR20260036605A (ko) 2026-03-17
SG11202110718PA (en) 2021-10-28
CO2021014210A2 (es) 2022-01-17
CN114258391A (zh) 2022-03-29
EP3947349B1 (en) 2026-03-11
AU2020253444B2 (en) 2025-05-29
US11771680B2 (en) 2023-10-03
KR20220004996A (ko) 2022-01-12
CN121085825A (zh) 2025-12-09
US20220071957A1 (en) 2022-03-10
FI3947349T3 (fi) 2026-04-23
PH12021552513A1 (en) 2022-10-03
EP4733305A2 (en) 2026-04-29
WO2020205934A1 (en) 2020-10-08
AU2020253444A1 (en) 2021-10-14
IL286902B1 (en) 2024-11-01
JP2022522312A (ja) 2022-04-15
US20200323821A1 (en) 2020-10-15
BR112021019817A2 (pt) 2021-12-07
JP7627008B2 (ja) 2025-02-05
CN121108034A (zh) 2025-12-12
JP7710215B2 (ja) 2025-07-18
IL286902A (en) 2021-10-31
MA55564A (fr) 2022-02-09
IL286902B2 (en) 2025-03-01
EP3947349A4 (en) 2022-11-23
US12599582B2 (en) 2026-04-14
JP2025146846A (ja) 2025-10-03
CA3134635A1 (en) 2020-10-08
JP2024153620A (ja) 2024-10-29
PE20220252A1 (es) 2022-02-16
DK3947349T3 (da) 2026-03-30
CL2021002575A1 (es) 2022-04-29
UA129029C2 (uk) 2024-12-25
TWI846853B (zh) 2024-07-01
GEAP202515762A (en) 2025-02-10
MX2021012105A (es) 2021-11-03

Similar Documents

Publication Publication Date Title
AU2020253444C1 (en) Pyrrole compounds
WO2020214728A1 (en) Bicyclic and tricyclic compounds
EP3924357A1 (en) Bicyclic sulfonamides
CA3195542A1 (en) Bicyclic compounds
EP4594319A1 (en) Bicyclic compounds
OA22136A (en) Pyrrole compounds.
EA046720B1 (ru) Соединения пиррола
AU2023257365A1 (en) Bicyclic compounds
WO2020247504A1 (en) Heterocyclic compounds

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 14 AUG 2025

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 14 AUG 2025

FGA Letters patent sealed or granted (standard patent)